PRISMAX/PRISMAFLEX Systems provide the truly slow continuous treatment that critically ill patients may require

Download White Paper

Easily Switch Between Therapies

PRISMAX and PRISMAFLEX Systems deliver multiple modes of Continuous Renal Replacement Therapy (CRRT) without the need for additional equipment.

CVVHDF: Continuous Veno-Venous Hemodiafiltration

CVVHD: Continuous Veno-Venous Hemodialysis

CVVH: Continuous Veno-Venous Hemofiltration

SCUF: Slow Continuous Ultrafiltration

Pharmacist looking at solution

Simplify Electrolyte Management With Our Comprehensive Portfolio of CRRT Solutions

  • Ready to use: Premixed solutions may help minimize preparation time, waste, and potential for medication errors1,2
  • Flexible: Available in a wide range of bicarbonate buffered solutions with various ionic formulations
  • Self-sealing: All solutions are packaged in two-compartment bags with self-sealing luer lock capability
  • On-label: A wide range of replacement solutions allow for security of on-label delivery of all CRRT modalities
Label of PHOXILLUM solution for CRRT.


The ONLY FDA-approved premixed CRRT replacement solution with phosphate, available in 2 formulations

Label of PRISMASOL Solution.


Standard replacement solution available in seven formulations

Label of PRIMASATE Solution.


Standard dialysate solution available in seven formulations

Featured Presentation
Pam Waters, RN presents presentation on CRRT Pre and Post Replacement Solutions

Pam Waters, RN, explains the uses and benefits of CRRT replacement solutions, and the differences between pre- and post- replacement solutions.

The PRISMAFLEX and PRISMAX Systems are intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.

Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicated.

Rx Only. For safe and proper use of products mentioned herein refer to the appropriate Instructions for Use or Operator's Manual.

PHOXILLUM and PRISMASOL Renal Replacement Solution Indications and Important Risk Information

Indications and Usage 
PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

Warnings and Precautions 
Electrolyte and Volume Abnormalities
PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis.

Blood Glucose Abnormalities
The use of PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.

Please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information.

MARS is indicated for the treatment of drug overdose and poisonings. The only requirement is that the drug or chemical be dialyzable (in unbound form) and bound by charcoal and/or ion exchange resins.

MARS is not indicated for the treatment of chronic liver disease conditions or as a bridge to liver transplant. Safety and efficacy has not been demonstrated for those indications in controlled, randomized clinical trials. The effectiveness of the MARS device in patients that are sedated could not be established in clinical studies and therefore cannot be predicted in sedated patients.